ORY — ORYZON Genomics SA Share News
0.000.00%
Last trade - 00:00- €204.89m
- €196.06m
Brief: Oryzon To Address FDA Feedback Regarding Phase III Of Vafidemstat And Resubmit Protocol
Brief: Oryzon Strengthens Patent Portfolio For Iadademstat With European Grant Decision Covering Combinations With Pd1/Pd-L1 Inhibitors
Brief: Oryzon To Sponsor Phelan-McDermid Syndrome Burden Of Illness Study
Spanish stocks - Factors to watch on Sept 16
Brief: Oryzon Expands Patent Portfolio For Iadademstat And Vafidemstat
Brief: Oryzon Receives European Medicines Agency Approval To Initiate A Phase Ib Study Of Iadademstat In Sickle Cell Disease
Brief: Oryzon Gets EMA Approval For Phase Ib Study Of Iadademstat In Sickle Cell Disease
Brief: Oryzon Genomics Q2 Income From Operations USD -4.344 Million
Brief: Oryzon H1 Net Loss At 1.6 Mln Euros
Brief: Oryzon Receives 'Decision To Grant' Communications From Canada And Israel For Vafidemstat Patent Applications
Brief: Oryzon Announces Submission Of Phase Iii Protocol To FDA To Initiate Portico-2 Trial
Brief: Oryzon Submits Phase III Trial Protocol For BPD Drug Vafidemstat To FDA
Brief: ORYZON To Provide Corporate Progress Updates At Several Events In May-June
Spanish stocks - Factors to watch on May 12
Brief: Oryzon Q1 Net Loss 1.7 Mln Euros
Spanish stocks - Factors to watch on May 8
Brief: Oryzon - Receives Non-Refundable Grant Of 13.26 Mln Euro For Its Vandam Project Within Med4cure
Brief: Oryzon Raises EUR 30 Million In Capital Increase
Spanish stocks - Factors to watch on April 24